KALY - Green Lighted and Recommended as Screaming "BUY" Following Patented Cannabis Extraction Acquisition
November 16 2018 - 8:55AM
InvestorsHub NewsWire
New York, NY – November 16, 2018 --
InvestorsHub NewsWire -- Kali, Inc. (USOTC:
KALY) is recommended as a “BUY” today by AmericBulls.com
following yesterday’s announcement that KALY had finalized the
acquisition of NCM Biotech, the developer and owner of a patented
cannabis extraction process - U.S. Patent No. 9,199,960 entitled
“METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS
INCLUDING THE CANNABIS PLANT.” The KALY news reported the
company plans to leverage the patent to enter the cannabis
pharmaceuticals and concentrates market. The news yesterday
further reported that the cannabis pharmaceuticals market is
forecasted to reach $50 billion in sales by 2029, and
that the cannabis concentrates for wellness, edibles and
recreational markets is forecasted to reach $8.5 billion in annual sales by
2022.
AmericanBulls.com:
“Our
system’s recommendation today is to BUY. The BULLISH
HARAMI pattern finally received a confirmation because the
prices crossed above the confirmation level which was at 0.0038,
and our valid average buying price stands now at 0.0039
…
The green light is on and this
security is now screaming BUY. It is action time! The bullish
pattern that was previously identified is finally confirmed and
a BUY signal is generated. Most probably, it is the right time
to participate in bullish fervor. Do not miss this bullish
opportunity.”
KALY’s news yesterday included more
information on the company’s plans to expand with a differentiated
service in the cannabis pharmaceuticals and concentrates
sector. “Kali, with its recent acquisition of NCM Biotech,
has separately announced entering into a joint venture (JV) company
called US Cannabis Health with Puration [PURA] and Nouveau life
Pharmaceuticals (USOTC: NOUV).”
Notably, the news yesterday
emphasized that KALY had no plans for a reverse split in
conjunction with the patented cannabis extraction
acquisition.
In reference to what all comes with
the acquisition, KALY’s news yesterday included the
following:
“NCM Biotech’s current research and
ongoing pharmaceutical developments come with the
acquisition. Commenting on the research NCM Biotech has
undertaken with notable medical institutions in the North East,
Frederick Ferri, CEO and Founder of NCM Biotech said, “Some
feedback has specifically indicated that a number of our candidate
pharmaceutical products under development have a greater efficacy
potential than GW Pharmaceutical [GWPH] products
and candidate products. “ “
DISCLAIMER: NextBigTicker.com
(NBT)is a third party publisher and news dissemination service
provider. NBT is NOT affiliated in any manner with any company
mentioned herein. NBT is news dissemination solutions provider and
are NOT a registered broker/dealer/analyst/adviser, holds no
investment licenses and may NOT sell, offer to sell or offer to buy
any security. NBT's market updates, news alerts and corporate
profiles are NOT a solicitation or recommendation to buy, sell or
hold securities. The material in this release is intended to be
strictly informational and is NEVER to be construed or interpreted
as research material. All readers are strongly urged to perform
research and due diligence on their own and consult a licensed
financial professional before considering any level of investing in
stocks. All material included herein is republished content
and details which were previously disseminated by the companies
mentioned in this release or opinion of the writer. NBT is not
liable for any investment decisions by its readers or subscribers.
Investors are cautioned that they may lose all or a portion of
their investment when investing in stocks. NBT has not been
compensated for this release and HOLDS NO SHARES OF ANY
COMPANY NAMED IN THIS RELEASE.
Disclaimer/Safe
Harbor:
This news release contains
forward-looking statements within the meaning of the Securities
Litigation Reform Act. The statements reflect the Company's current
views with respect to future events that involve risks and
uncertainties. Among others, these risks include the expectation
that any of the companies mentioned herein will achieve significant
sales, the failure to meet schedule or performance requirements of
the companies' contracts, the companies' liquidity position, the
companies' ability to obtain new contracts, the emergence of
competitors with greater financial resources and the impact of
competitive pricing. In the light of these uncertainties, the
forward-looking events referred to in this release might not
occur.
Source: www.nextbigticker.com
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Apr 2024 to May 2024
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Puration Inc (CE) (OTCMarkets): 0 recent articles
More Puration Inc. (PC) News Articles